June 29, 2021 05:43 PM EDTUpdated June 30, 06:43 AM

Is 9 years too long to run a confirmatory study for a drug like aducanumab? In Sarepta’s case, it isn’t enough time

The storm of controversy that broke over the FDA’s decision to provide an accelerated approval for aducanumab proved contentious on several levels. And near the …

This article is available only to Premium subscribers

Upgrade to Premium for unlimited access and Premium exclusives.

UPGRADE

Is 9 years too long to run a confirmatory study for a drug like aducanumab? In Sarepta’s case, it isn’t enough time

This article is available only to Premium subscribers

PTC reports Phase 2 ALS fail, sells priority review voucher for $150M

Norbert Bischofberger's time as Kronos CEO ends as biotech seeks new life

FDA is looking into hematology risks after patients take Bluebird's Skysona gene therapy

Sarepta licenses Arrowhead's RNA-based rare disease pipeline, promising big biobucks

To lead NIH, Trump taps Stanford academic and pandemic response critic Jay Bhattacharya

Applied Therapeutics' rare disease drug gets a CRL

Is 9 years too long to run a con­fir­ma­to­ry study for a drug like ad­u­canum­ab? In Sarep­ta’s case, it isn’t enough time

This article is available only to Premium subscribers

more like this

PTC re­ports Phase 2 ALS fail, sells pri­or­i­ty re­view vouch­er for $150M

Nor­bert Bischof­berg­er's time as Kro­nos CEO ends as biotech seeks new life

FDA is look­ing in­to hema­tol­ogy risks af­ter pa­tients take Blue­bird's Skysona gene ther­a­py

Sarep­ta li­cens­es Ar­row­head­'s RNA-based rare dis­ease pipeline, promis­ing big biobucks

To lead NIH, Trump taps Stan­ford aca­d­e­m­ic and pan­dem­ic re­sponse crit­ic Jay Bhat­tacharya

Ap­plied Ther­a­peu­tic­s' rare dis­ease drug gets a CRL

Is 9 years too long to run a confirmatory study for a drug like aducanumab? In Sarepta’s case, it isn’t enough time

PTC reports Phase 2 ALS fail, sells priority review voucher for $150M

Norbert Bischofberger's time as Kronos CEO ends as biotech seeks new life

FDA is looking into hematology risks after patients take Bluebird's Skysona gene therapy

Sarepta licenses Arrowhead's RNA-based rare disease pipeline, promising big biobucks

To lead NIH, Trump taps Stanford academic and pandemic response critic Jay Bhattacharya

Applied Therapeutics' rare disease drug gets a CRL